• No results found

Making Meaningful Improvements in Pharmacotherapy and Medication Management for Children and Youth-A Modest Proposal

N/A
N/A
Protected

Academic year: 2021

Share "Making Meaningful Improvements in Pharmacotherapy and Medication Management for Children and Youth-A Modest Proposal"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

children

Editorial

Making Meaningful Improvements in

Pharmacotherapy and Medication Management for

Children and Youth—A Modest Proposal

Richard H. Parrish II1,2,* , Johannes van den Anker3,4,5 and Sandra Benavides6 1 St. Christopher’s Hospital for Children, 160 E. Erie Avenue, Philadelphia, PA 19134, USA 2 Virginia Commonwealth University, School of Pharmacy, Richmond, VA 23298, USA 3 Universitäts-Kinderspital beider Basel (UKBB), Spitalstrasse 33, CH-4031 Basel, Switzerland;

JohannesN.VandenAnker@ukbb.ch

4 Children’s National Health System, 111 Michigan Avenue, Washington, DC 20010, USA

5 Erasmus Medical Center—Sophia Children’s Hospital, s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands

6 PRIME Education, Miami, FL 33169, USA; sandra.b.caballero@gmail.com * Correspondence: richardhenryparrish2@gmail.com; Tel.:+1-215-427-5317

Received: 7 October 2019; Accepted: 8 October 2019; Published: 9 October 2019  Keywords:children; youth; clinical pharmacy; pediatrics; medication management; medical complexity

The Special Issue, “Development of a National Pediatric Pharmacotherapy Collaborative Practice Network,” has illuminated the vital global need for better care coordination and interprofessional collaboration in pharmacotherapy and medication management of children with medical complexity and special healthcare needs (CSHCN-CMC). From a population health perspective, we identified how coordination and outcomes might be improved from both practice and research perspectives, and what tools exist to assist clinical pharmacists and pediatricians to build more durable and sustainable comprehensive medication management practices around the world [1,2]. The work of the Professional Compounding Centers of America (PCCA) group [3] and ‘GOLDILOKs’ (Genome and Ontogeny-Linked Dose Individualization and cLinical Optimization for KidS) Clinic [4] illustrated personalized approaches to identifying, understanding, and responding to these patients’ unique drug therapy needs with evidence-based compounded formulations and genome-informed care planning. Ohio’s Partners for Kids Accountable Care Organization (ACO) provided a comprehensive, systems-based program for including clinical pharmacists to address inefficiencies in care coordination and delivery, especially in children with asthma and behavioral health needs [5]. The development and inclusion of clinical pharmacists within maternal child health strategies of the Health Resources and Services Administration’s Pediatric Pulmonary Center in Arizona fostered improvements in community-based, family-centered healthcare for children with chronic respiratory diseases [6]. Clearly, these approaches portend increased responsiveness to unmet drug-related needs at individual and system levels of analysis.

What’s next? To continue to build on these successes, the following recommendations are offered: 1. Creation of interprofessional communities of practice and research that share tacit knowledge through various synchronous and asynchronous delivery media to promote point-of-care collaboration and coordination;

2. Application of administrative leadership and vision that promotes an environment of innovation through sustainable provider-patient-payer partnerships and outcome-driven system transformation;

(2)

Children 2019, 6, 111 2 of 2

3. Adoption and expansion of patient engagement functionalities that align with the 21st Century Cures Act and the World Health Organization’s Convention on the Rights of the Child for increasing choice, access, equity, and quality in health care.

We believe this modest proposal will generate meaningful improvements that assure all children receive optimal benefit from pharmacotherapies. We thank the authors and readers of these manuscripts, and hope that this dialogue will continue to build more durable and sustainable care coordination systems locally and beyond.

References

1. Parrish, R.H., II; Casher, D.; van den Anker, J.; Benavides, S. Creating a Pharmacotherapy Collaborative Practice Network to Manage Medications for Children and Youth: A Population Health Perspective. Children (Basel) 2019, 6, 58. [CrossRef] [PubMed]

2. Parrish, R.H., II; van den Anker, J. Toolkit for Population Health Initiatives Around the Globe Related to Collaborative Comprehensive Medication Management for Children and Youth. Children (Basel) 2019, 6, 57.

[CrossRef] [PubMed]

3. Heitman, T.; Day, A.J.; Bassani, A.S. Pediatric Compounding Pharmacy: Taking on the Responsibility of Providing Quality Customized Prescriptions. Children (Basel) 2019, 6, 66. [CrossRef] [PubMed]

4. Sandritter, T.L.; Dinh, J.C.; Wagner, J.A.; Lowry, J.A. Description of an Innovative Pediatric Individualized Therapeutics Clinic: Working toward Precision Drug Therapy. Children (Basel) 2019, 6, 35. [CrossRef]

[PubMed]

5. Hobart, C.; Daines, C.; Phan, H. Developing Future Clinical Pharmacy Leaders in the Interprofessional Care of Children with Special Health Care Needs and Medical Complexity (CSHCN-CMC) in a Pediatric Pulmonary Center. Children (Basel) 2019. under review.

6. Kuhn, C.; Groves, B.K.; Kaczor, C.; Sebastian, S.; Ramtekkar, U.; Nowack, J.; Toth, C.; Valenti, O.; Gowda, C. Pharmacist Involvement in Population Health Management for a Pediatric Managed Medicaid Accountable Care Organization. Children (Basel) 2019, 6, 82. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Referenties

GERELATEERDE DOCUMENTEN

Het nieuwe artikel 10a van de Advocatenwet biedt nu een (formeel) wettelijk kader voor de vijf kernwaarden van de Nederlandse advocatuur: onafhankelijkheid, partijdigheid,

An option that was explicitly recognized by both the Enlarged Board of Appeal and the Supreme Court is to turn to the other patentability requirements for the exclusion of

The surrogate model is now known and can be used in the next optimisation phase where the overall surrogate response R s goals are minimised to nd the next optimal design

Having gained a clearer picture of Jaynes’ general bicameral paradigm, we will then go on to examine how this paradigm relates to modern consciousness and, finally, how our hypnotic

We selected principles from international human rights law that concern States’ obligations towards social or health rights, the core obligation to provide essential medicines,

Based on these results it is observed that, although tendencies of changes in concentrations are present, the values in the second half of January are not back to the

The three competences that will gain most importance in the next ten years, according to the European professionals, are: selecting information, account for journalistic work

Question 3: Do differences in soil characteristics (organic matter, acidity, texture and surrounding vegetation) have a significant influence on tree growth and health of the